Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2022-02-14 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
安徽承义律师事务所关于华兰生物工程股份有限公司2018年限制性股票激励计划首次授予的限制性股票第三个解除限售期解锁条件成就的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the achievement of conditions for the third unlocking period of restricted stock granted under a 2018 restricted stock incentive plan by a company. It details the legal compliance, approval procedures, and conditions met for the unlocking of restricted shares. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to stock incentive plan unlocking conditions. It is a standalone legal proceeding document related to regulatory compliance and stock incentive unlocking, which fits best under Legal Proceedings Report (LTR).
2022-02-14 Chinese
关于2018年限制性股票激励计划首次授予的限制性股票第三个解除限售期解锁条件成就的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the achievement of unlocking conditions for the third unlocking period of restricted stocks granted under the company's 2018 restricted stock incentive plan. It details the board and supervisory approvals, legal opinions, and the number of shares and participants involved in the unlocking. It does not contain financial statements or detailed financial performance data but rather focuses on the status and approval of stock incentive plan unlocking events. This type of document is a regulatory announcement related to share-based compensation and stock incentive plans, typically classified as a Regulatory Filing (RNS) because it is an official disclosure about corporate governance and stock incentive plan progress, not a full report or financial statement. The document length is sufficient and detailed but does not constitute an annual report, audit report, or management report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-02-14 Chinese
关于控股子公司华兰生物疫苗股份有限公司在创业板首次公开发行股票获中国证监会注册的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval and registration of a subsidiary's initial public offering (IPO) on the ChiNext board, including references to regulatory approvals by the China Securities Regulatory Commission and the Shenzhen Stock Exchange. It is not a financial report, earnings release, or detailed investor presentation but rather a formal announcement of a capital market event related to stock issuance and listing. The document length is short (657 characters) and it announces the registration approval for the IPO, which fits the category of Capital/Financing Update (CAP).
2022-01-12 Chinese
关于控股子公司通过高新技术企业重新认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (750 characters) from a company about its subsidiary passing a high-tech enterprise re-certification, which affects tax treatment for the next three years. It does not contain financial statements, detailed financial data, or management discussion. It is an official regulatory announcement about a corporate status update related to tax benefits. It is not an annual report, earnings release, or any detailed financial report. It is also not a voting result, board change, or capital update. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous official announcements that do not fit other specific categories.
2022-01-05 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第三季度报告' which translates to '2021 Third Quarter Report'. It contains detailed financial data including income, net profit, cash flow, earnings per share, and balance sheet items as of September 30, 2021. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the third quarter of 2021. It is not a brief announcement or a certification letter but a full interim financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-10-29 Chinese
关于董事长、总经理增持本公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the increase in shareholding by the company's chairman and general manager. It details the number of shares purchased, the price, dates, and the percentage of total shares held before and after the transaction. It also references compliance with relevant securities laws and regulations. This type of document is a report of personal share transactions by company directors and executives, which fits the definition of Director's Dealing (DIRS). The document length is short and focused solely on this shareholding change, with no financial statements or other report content.
2021-09-15 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.